Steris plc stock (IE00BFY8C754): Q4 2026 earnings due today with consensus revenue forecast

Steris plc releases Q4 fiscal 2026 earnings after market close today, with analysts forecasting $1.60 billion in revenue and EPS of $2.89 amid tariff concerns.

Steris plc, listed on NYSE under ticker STE, is scheduled to report its fiscal fourth quarter 2026 earnings on May 11, 2026, after the market close. Consensus estimates call for revenue of $1.60 billion and earnings per share of $2.89, according to Intellectia AI as of May 2026. The earnings call is set for 16:30 ET, highlighting recent revenue growth of 7.96% and operating income expansion of 13.56% over the trailing twelve months, as noted in Investing.com as of May 2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Steris plc
• Sector/industry: Medical equipment and sterilization
• Headquarters/country: Ireland (US operations)
• Core markets: US healthcare system
• Key revenue drivers: Infection prevention products
• Home exchange/listing venue: NYSE (STE)
• Trading currency: USD

Steris plc: core business model

Steris plc develops, manufactures, and supports equipment and consumables focused on infection prevention and contamination control for healthcare and life sciences. The company provides sterilization technologies, surgical support products, and services critical to hospitals and surgical centers, primarily in the US market. This positioning makes Steris a key player for US investors tracking healthcare supply chain resilience, as detailed in its Google Finance profile as of May 2026.

Main revenue and product drivers for Steris plc

Revenue stems from sterilization processing systems, consumables like sterile packaging, and high-end surgical tables and lights. The US healthcare system drives the majority of sales, with products aimed at reducing infection risks in procedures. Over the trailing twelve months ending before May 2026, Steris reported 7.96% revenue growth, per Investing.com as of May 2026.

Industry trends and competitive position

The medical sterilization sector benefits from rising demand for infection control amid post-pandemic hygiene standards. Steris competes with players like Fortive and Getinge, holding a strong foothold in US hospitals through service contracts and recurring consumable sales. Tariff headwinds on imports could pressure margins, as highlighted ahead of today's earnings.

Why Steris plc matters for US investors

With primary listing on NYSE and deep ties to the US healthcare system, Steris offers exposure to defensive medical consumables less sensitive to elective procedure cycles. Its products support infection prevention in over 100 million annual US procedures, providing stability for portfolios focused on healthcare essentials.

Conclusion

Steris plc approaches its Q4 2026 earnings with solid trailing growth metrics but faces scrutiny over tariff impacts and margin sustainability. Investors will watch for guidance on revenue expansion and free cash flow, building on prior 15% EPS gains noted in forecasts. The release provides key insights into healthcare sector dynamics relevant to US markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.